Core Laboratories Q4 EPS Beats Estimates, Revenues $138.3M, Costs Up 6.4%
Core Laboratories reported Q4 adjusted EPS of $0.21, topping the $0.20 estimate, as revenues rose 7% to $138.3 million and beat the $132 million forecast. Total costs climbed 6.4% year-over-year, while the company repurchased 363,207 shares for $5.7 million, reduced net debt by $1.2 million and declared a $0.01 dividend.
1. Q4 Financial Highlights
Core Laboratories delivered adjusted earnings of $0.21 per share in Q4, surpassing the $0.20 consensus. Operating revenues reached $138.3 million, up 7% from the prior year and above the $132 million estimate, driven by strong demand for laboratory analytical services and completion diagnostics internationally.
2. Expense and Capital Actions
Total costs and expenses rose 6.4% to $122.4 million, reflecting higher operating expenses across segments. The company repurchased 363,207 shares for $5.7 million, reduced net debt by $1.2 million and maintained cash of $22.8 million against $110.3 million in long-term debt.
3. Dividend and Outlook
The board declared a quarterly cash dividend of $0.01 per share, unchanged from the prior period. For Q1 2026, revenues are projected between $124 million and $130 million with EPS of $0.11–$0.15, anticipating softer U.S. land activity offset by international demand and proprietary technology uptake.